$ONVO Up to date company activities and other important

New Post Public Reply Private Reply Replies (0) Message Board
Emylers
$ONVO Up to date company activities and other important information about $ONVO

$ONVO

DD Notes ~ http://www.ddnotesmaker.com/ONVO

##### recent news/filings ~ source: finance.yahoo.com

Wed, 20 Nov 2013 21:57:15 GMT ~ ORGANOVO HOLDINGS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
read full: http://biz.yahoo.com/e/131120/onvo8-k.html
*********************************************************

Wed, 20 Nov 2013 18:38:22 GMT ~ 3D Printing Stocks Pummeled for a Second Straight Day
- Every one of the 3D printing stocks we follow got pounded on Tuesday and apparently the beatings will continue until morale improves. Wednesday trading has the stocks down in the early afternoon by just ...
read full: http://finance.yahoo.com/news/3d-printing-sto...22205.html
*********************************************************

Wed, 20 Nov 2013 14:08:41 GMT ~ Organovo At The Mercy Of The Media
- Organovo ( ONVO ) has gained tremendous attention in the market over the past year. The stock began 2013 at below $3.00 but recently rose as high at $13.65. In October, the stock was trading around $5.50, ...
read full: http://seekingalpha.com/article/1851531-organ...urce=yahoo
*********************************************************

Wed, 20 Nov 2013 14:07:48 GMT ~ InPlay: Organovo provides guidance on topics to be discussed at an upcoming investor conference on Dec 5, 2013; company plans to launch an initial 3D liver tissue assay product in 2014
read full: http://finance.yahoo.com/mp#onvo
*********************************************************

Wed, 20 Nov 2013 14:05:00 GMT ~ Organovo Provides Guidance on Upcoming Retail Investor Conference
- SAN DIEGO, Nov. 20, 2013 /PRNewswire/ -- Organovo Holdings, Inc. (NYSE MKT: ONVO) ("Organovo"), a three-dimensional biology company focused on delivering breakthrough 3D bioprinting technology, today provided guidance on topics to be discussed at an upcoming Retail Investor Conference on December 5, 2013. Product pipeline and revenue potential: As described previously in the company's presentations and investor communications, including the freely available Retail Investor Conference from September 12, 2013, the company plans to launch an initial 3D liver tissue assay product in 2014, followed by a series of additional tissue assay products. Based on market research, Organovo believes that each of the product opportunities it has identified can grow into the tens of millions in annual revenue and has a $100M+ addressable market, with an overall market opportunity of $500M across all tissue products by 2018. Beyond this market opportunity, defined by sales of current cell based models, also lies the opportunity to develop products and services for the multibillion dollar animal preclinical testing market for pharmaceutical, cosmetic, and environmental industries.
read full: http://finance.yahoo.com/news/organovo-provid...00862.html
*********************************************************

##### chart ~ source: stockcharts.com

stockcharts.com/c-sc/sc?s=ONVO&p=D&b=5&g=0&id=p95448242713

##### chart ~ source: eoddata.com

http://chart.eoddata.com/?e=OTCBB&s=ONVO&...D&b=BB

##### company info ~ source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/ONVO/company-info
Ticker: $ONVO
OTC Market Place: Not Available
CIK code: 0001497253
Company name: Organovo Holdings, Inc.
Company website: http://www.organovo.com
Incorporated In: DE, USA

##### extra dd links

Edgar filings: http://www.sec.gov/cgi-bin/browse-edgar?actio...p;count=40
Latest filings: http://www.otcmarkets.com/stock/ONVO/filings
Latest financials: http://www.otcmarkets.com/stock/ONVO/financials
Latest news: http://www.otcmarkets.com/stock/ONVO/news - http://finance.yahoo.com/q/h?s=ONVO+Headlines

Major holdings: http://data.cnbc.com/quotes/ONVO/tab/8.1
Insider transactions (1): http://finance.yahoo.com/q/it?s=ONVO+Insider+Transactions
Insider transactions (2): http://www.secform4.com/insider-trading/ONVO.htm
Insider transactions (3): http://www.insidercow.com/history/company.jsp?company=ONVO

RegSho: http://www.regsho.com/tools/symbol_stats.php?...rch=search

DTCC: http://search2.dtcc.com/?q=Organovo+Holdings%...ISO-8859-1
Spoke company information: http://www.spoke.com/search?utf8=%E2%9C%93&am...ngs%2C+Inc.
Corporation WIKI: http://www.corporationwiki.com/search/results...=0&y=0
WHOIS: http://whois.domaintools.com/http://www.organovo.com
Alexa: http://www.alexa.com/siteinfo/http://www.organovo.com#
Corporate website internet archive: http://web.archive.org/web/*/http://www.organovo.com

http://www.pennystocktweets.com/stocks/profile/ONVO

##### last known share structure ~ source: otcmarkets.com

Market Value: $475,873,969 a/o Nov 19, 2013
Shares Outstanding: 76,507,069 a/o Aug 07, 2013
Float: 50,000,000 a/o Mar 31, 2013
Authorized Shares: 150,000,000 a/o Feb 03, 2012
Par Value: 0.001

##### business description ~ source: otcmarkets.com

Organovo designs and creates functional human tissues using a proprietary three dimensional bioprinting technology. The Company focuses on developing a range of human tissues and disease models for medical research and therapeutic applications. The Company's NovoGen? three-dimensional bioprinting technology employs a specialized automated platform that works across all tissue and cell types. Organovo?s bioprinter was named one of the ?Best Inventions of 2010? by TIME Magazine and Organovo has... read more: http://www.otcmarkets.com/stock/ONVO/company-info

DD Notes ~ http://www.ddnotesmaker.com/ONVO

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ivonescimab Promises New Hope for Advanced BTC Patients

Updated Category News Views 313

Shifting the Paradigm in Biliary Tract Cancer Treatment Here's the scoop from the bustling world of oncology: the trial of Ivonescimab plus chemotherapy is stirring waves among experts in advanced biliary tract cancer (BTC). Contrary to the usual drowsy mornings with coffee and market pages, this data from Hong Kong wasn't about Wall Street this time. This trial might...

Continue Reading
Monster Energy Unleashes Gaming Frenzy at Cosm L.A. Event

Updated Category News Views 193

Where Energy Drinks and Digital Reality Collide Monster Energy sure knows how to throw a party, especially when it hinges on something as electrifying as Call of Duty: Modern Warfare 4. Imagine this: Cosm Los Angeles is decked out with a massive 87-foot LED dome, and every gamer, celeb, and influencer ready to dive right in. You can't make this stuff up. They've mashed...

Continue Reading
Firefox Champions Privacy with Iconic Internet Campaign

Updated Category News Views 128

Rekindling the Internet’s Golden Days with Firefox There’s something almost poetic about Firefox hustling to win back its old users by launching a campaign with legendary internet icons. The backdrop? A digital landscape where privacy feels about as common as a unicorn sighting. Mozilla's pulling a major nostalgia card, and I'm here for it—sort of like how vinyl...

Continue Reading
DigitalXForce Shakes Up GRC: AI-Infused X-ROC Launch

Updated Category News Views 130

Turning Risk Management on Its Head Well, here's a company not just tinkering around the edges but flipping the script on Governance, Risk, and Compliance (GRC) with their latest rollout: DigitalXForce and its X-ROC. Yeah, it's yet another acronym to juggle, but don't roll your eyes just yet. This AI-driven beast isn't about occasional boardroom reports. No sir, it's a...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 258

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Hims & Hers Faces FTC Heat: Investor Class Action Looms

Updated Category News Views 224

Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...

Continue Reading
Innovent's IBI3001 Shows Promise in Phase 1 Trials

Updated Category News Views 332

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Continue Reading
Dr. Boonipat Inspires Future Women Surgeons at Texas Tech

Updated Category News Views 134

Sowing Surgical Seeds in Lubbock In Lubbock, Texas, something meaningful unfolded—an event the big market players would hardly blink at, but a significant step for the future of medicine. Led by Dr. Thanapoom "Mo" Boonipat, the founder of FacePlus Plastic Surgery Institute, a unique suturing workshop provided premed students at Texas Tech University hands-on experience...

Continue Reading
Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

Updated Category News Views 541

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Continue Reading
Tennessee's Bold Lung Cancer Trial Signals Innovation

Updated Category News Views 161

The Heartbeat of Innovation in Cancer Therapy Who would've thought Tennessee would be at the forefront of a global push against lung cancer? Sure, there's Nashville's music scene, but it's the researchers at Tennessee Oncology who are grooving to a different beat—one that might just set the rhythm for advanced cancer therapies worldwide. Yeah, it's a trial, but not just...

Continue Reading

Top 5 Most Recently Viewed Articles

Phreesia Announces Q3 Fiscal Year 2025 Financial Results

Updated Category News Views 71

Phreesia to Release Fiscal Q3 2025 Results Soon Phreesia, Inc. (NYSE: PHR) has great news for its stakeholders! The company revealed plans to announce its financial results for the third quarter of fiscal year 2025 right after market closing on a Monday in December. During this quarter, the firm experienced substantial growth and is eager to share the details with the...

Continue Reading
Innovative Water Bowl Design Enhances Pet Hydration Experience

Updated Category News Views 374

Revolutionary Pet Water Bowl Crafted for Optimal Hydration Every pet owner knows the importance of keeping their furry friends hydrated, especially during hot days. A new invention promises to enhance the experience for pets and their owners alike. This innovative water bowl, known as the THERMA DRINK, is designed with features that cater directly to pet needs. The idea...

Continue Reading
HPH's Leadership Changes Signify Strategic Direction Ahead

Updated Category News Views 177

Leadership Transitions at HPH Highest Performances Holdings Inc. (NASDAQ: HPH) has recently seen a notable change in its Board of Directors. The company announced that Mr. Peh Chin Hua's tenure as Director has come to an end, effective immediately. This decision is part of a broader strategy aimed at strengthening the Board's overall composition and capabilities. Current...

Continue Reading
Apranga Group Reports Growth in Retail Turnover for 2025

Updated Category News Views 132

Apranga Group Retail Performance Overview for 2025 Apranga Group, a major player in the retail sector, has announced its impressive financial performance for the first six months of 2025, demonstrating notable growth compared to the prior year. The company's retail turnover reached a commendable EUR 166.1 million, reflecting a 2.8% increase from the same period in 2024....

Continue Reading
IMUNON Unveils Promising New Vaccine Data for COVID-19

Updated Category News Views 154

New Vaccine Insights from IMUNON's Phase 1 Clinical Trial The innovative PlaCCine technology platform developed by IMUNON, Inc. (NASDAQ: IMNN) promises remarkable durability and advantages over traditional mRNA vaccines, particularly in the struggle against COVID-19. Robust Results from IMNN-101 Vaccine Trials In an encouraging announcement, IMUNON shared pivotal data...

Continue Reading